22:55 , Sep 7, 2018 |  BC Extra  |  Company News

Amid launch troubles, Portola commercial chief Fu resigns

With its stock price near its 52-week low amid a disappointing launch of anticoagulant Bevyxxa betrixaban, Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said EVP and Chief Commercial and Business Officer Tao Fu is resigning to pursue other...
03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with...
17:51 , May 11, 2018 |  BC Week In Review  |  Clinical News

FDA approves Portola's Andexxa

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) added about $570 million in market cap on May 4 after FDA granted accelerated approval to a resubmitted BLA for its Andexxa andexanet alfa. The agency approved Andexxa to reverse the...
15:11 , May 4, 2018 |  BC Extra  |  Company News

Portola jumps on FDA approval of Andexxa

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) gained $8.66 (26%) to $42.44 on Friday after FDA granted accelerated approval to a resubmitted BLA for its Andexxa andexanet alfa. Portola announced the approval after market close on Thursday. The...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
17:22 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Portola reports additional Phase IIIb/IV data of Factor Xa inhibitor antidote AndexXa

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) reported data from 228 patients with Factor Xa inhibitor-associated acute major bleeding in the Phase IIIb/IV ANNEXA-4 trial showing that AndexXa andexanet alfa (IndexXa, PRT4445, PRT064445) led to “excellent or good”...
17:55 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

FDA may require additional trial of Portola's AndexXa

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) lost over $700 million in market cap on March 1 after it disclosed late on Feb. 28 that FDA may require an additional randomized study of AndexXa andexanet alfa to reverse...
23:31 , Mar 1, 2018 |  BC Extra  |  Company News

Portola sinks under AndexXa uncertainty

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) dropped $10.76 (25%) to $31.56 Thursday, losing over $700 million in market cap, after it disclosed late Wednesday that FDA may require an additional randomized study of AndexXa andexanet alfa to...
20:18 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

Portola expects CHMP to recommend andexanet alfa, but not betrixaban

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said EMA's CHMP communicated a "positive trend vote" for an MAA for AndexXa andexanet alfa (IndexXa, PRT4445, PRT064445) to reverse the anticoagulant effects of Factor Xa inhibitors. However, Portola said the...
23:25 , Jan 9, 2018 |  BioCentury  |  Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...